Susquehanna International Group’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
AIM
FCM
VPM
AVM
VCM
NAMA
Susquehanna International Group's BEAM Position: Q1 2026 in Review
Susquehanna International Group increased its Beam Therapeutics (BEAM) stake by 81% in Q1 2026, buying an estimated $2.22M and bringing the position to 178,391 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4544.
Susquehanna International Group first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $10M in Q2 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.
- Susquehanna International Group held 178,391 shares of Beam Therapeutics worth $4.25M as of Q1 2026.
- Susquehanna International Group bought 79,880 Beam Therapeutics shares in Q1 2026, an estimated $2.22M.
- Beam Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4544 holding.
- Susquehanna International Group first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
- Susquehanna International Group's Beam Therapeutics position peaked at $10M in Q2 2025.
- 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.